Marianne Grønlie Guren
机构: MD PhD, Oslo University Hospital
每年引用次数
引用次数
引用: 7,461
H-指数: 42
I10-指数 : 81
出版物: 182
Volume 32-No. 9-September 2021
S Derks , SPL Saw , DSW Tan , MJ Piccart
1742P Gender differences in incidence trends of early-onset GI cancer: The European perspective
I Ben-Aharon , HWM Van Laarhoven , MG Guren , I Baraibar Argota
Annals of Oncology 34 S945 -S945
2023
Treatment strategies and overall survival for incurable metastatic colorectal cancer–a EURECCA international comparison including 21,196 patients from the Netherlands and Norway
AJ Breugom , E Bastiaannet , MG Guren , H Kørner
European Journal of Surgical Oncology 46 ( 6) 1167 -1173
6
2020
52. Resection of the primary tumour for asymptomatic incurable metastatic colorectal cancer–A EURECCA international comparison
AJ Breugom , E Bastiaannet , MG Guren , H Kørner
European Journal of Surgical Oncology 42 ( 9) S86 -S87
2016
Highlights from the ESMO Annual Meeting 2023–EORTC GI Tract Group picks from the colorectal and anal cancer track
R Fazio , D Arnold , G Folprecht , MG Guren
ESMO Gastrointestinal Oncology 3
2024
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
Sheela Rao , Gayathri Anandappa , Jaume Capdevila , Laëtitia Dahan
ESMO open 7 ( 4) 100529 -100529
32
2022
Post-Operative Functional Outcomes in Early Age Onset Rectal Cancer
LV O’Connell , AM Zaborowski , A Abdile , M Adamina
Frontiers in Oncology 12
2022
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
S Rao , MG Guren , K Khan , G Brown
Annals of Oncology 32 ( 9) 1087 -1100
135
2021
Identifying patients who may benefit from adaptive radiotherapy: Does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help? CL Brouwer, RJHM Steenbakkers, JA Langendijk, NM Sijtsema (The Netherlands) 285 What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
NG Zaorsky , JD Palmer , MD Hurwitz , SW Keith
Radiotherapy and Oncology 115 ( 3) 285 -438
2015
Intensity modulated proton therapy planning study for organ at risk sparing in rectal cancer re-irradiation
HS Rønde , JF Kallehauge , CJS Kronborg , L Nyvang
Acta Oncologica 60 ( 11) 1436 -1439
4
2021
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H Sorbye , SFAU Welin , Seppo Wang Langer , Lene Weber Vestermark
Annals of Oncology 24 ( 1) 152 -160
937
2013
Dose-escalated pencil beam proton therapy for reirradiation of pelvic recurrences from rectal cancer
C Kronborg , HS Ronde , JF Kallehauge , MG Guren
RADIOTHERAPY AND ONCOLOGY 161 S1050 -S1051
2021
PO-1271 Dose-escalated pencil beam proton therapy for reirradiation of pelvic recurrences from rectal cancer
C Kronborg , HS Rønde , JF Kallehauge , MG Guren
Radiotherapy and Oncology 161 S1049 -S1050
2021
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
Samantha Claire Sodergren , A Hurley-Wallace , Vasilis Vassiliou , B Alkhaffaf
Gastric Cancer 1 -13
2024
PD-0791 VMAT plan complexity in dose painting
AM Acosta Roa , P Lønne , MG Guren , E Malinen
Radiotherapy and Oncology 161 S626 -S627
2021
Accurate population-based model for individual prediction of colon cancer recurrence
Erik Osterman , Joakim Ekström , Tobias Sjöblom , Hartwig Kørner
Acta Oncologica 60 ( 10) 1241 -1249
8
2021
PH-0216 Volumetric and dosimetric stability of metabolic tumor volume in dose painting of anal cancer
AM Acosta Roa , VE Skingen , BL Rekstad , MG Guren
Radiotherapy and Oncology 161 S148 -S149
2021
Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trends
MF Ystgaard , TÅ Myklebust , J Smeby , IK Larsen
ESMO Gastrointestinal Oncology 100065 -100065
2024
543P Tumor mutational burden (TMB), BRAF status, and C-reactive protein (CRP) predict response to first-line alternating oxaliplatin-based chemotherapy and nivolumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC)
AH Ree , PA Bousquet , HL Nilsen , T Lüders
Annals of Oncology 35 S453 -S453
2024
632P Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
S Meltzer , JP Berg , HM Hamre , C Kersten
Annals of Oncology 34 S449 -S449
2023